

VAKSIMUNE®
CORYZA COLI

COMPREHENSIVE CARE
CORYZA AND *E. COLI* VACCINE SOLUTION

vaksindo

VAKSIMUNE® Coryza Coli

Challenges & Our Commitment:

The poultry industry faces significant challenges with diseases such as colibacillosis and coryza caused by Escherichia coli and *Avibacterium paragallinarum*, respectively. The emergence of colibacillosis cases is often linked to the immunosuppressive effects of Gumboro, particularly in broilers, and as a co-disease with various other poultry ailments like Chronic Respiratory Disease, Infectious Coryza, Swollen Head Syndrome, Infectious Laryngotracheitis, and Coccidiosis. Antibiotic use, while common for bacterial disease control, poses risks such as *E. coli* resistance and disturbances to beneficial intestinal flora.

Features:

VAKSIMUNE® Coryza Coli is an inactivated Coryza and *E.Coli* vaccine, each dose contains :

Avibacterium paragallinarum bacteria serotype A (0083)	**> $10^{8.0}$ CFU**
Avibacterium paragallinarum bacteria serotype B (V5)	**> $10^{8.5}$ CFU**
Avibacterium paragallinarum bacteria serotype C (Modesto)	**> $10^{8.0}$ CFU**
Avibacterium paragallinarum bacteria serotype C (V26)	**> $10^{8.5}$ CFU**
Escherichia coli bacteria serotyype O1K1	**> $10^{9.0}$ CFU**
Escherichia coli bacteria serotype O2K1	**> $10^{9.0}$ CFU**
Escherichia coli bacteria serotype O78K80	**> $10^{9.0}$ CFU**

The vaccine is characterized by an excellent quality oil emulsion, which not only enhances its efficacy but also ensures safety for the vaccinated birds.



Vaccination Strategy for breeder/layer:
1st Vaccination : 10-14 Weeks
2nd Vaccnation : 16-20 Weeks

Vaccine Administration :
Vaccine can be administered via Intramuscular / subcutaneous injection

Packing size:
Available in 500 & 1000 Doses

VAKSIMUNE® Coryza Coli Benefits

Safe with 7 Strains in One

VAKSIMUNE® Coryza Coli targets a range of pathogens, giving your chickens a versatile defense against infections. It is formulated with four coryza strains and three *E. coli* strains.

Consistent Antibody Titers and Long-lasting Immunity

Serological tests consistently demonstrated a surge in antibody titers, showcasing the vaccine's effectiveness in ensuring enduring and robust immunity in chickens.

Minimized Clinical Symptoms and Mortality

Protect your chickens from coryza and *E Coli* infection with this effective vaccine. It reduces symptoms, mortality, and losses.



Coryza Antibody Serology Result

The results of Coryza serological tests (HI) on all serum samples from the group of chickens vaccinated with Vaksimune Coryza-Coli (A, B, C, and D) showed a clear increase in antibody titers every week until the 3rd week after vaccination. The minimum titer for protection is 3.3, and all serotypes produced titers higher than the required threshold.

Group	Challenge Using Antigen	Mortality	Protective (%)	PA Score Mean		
				Air Sacculitis	Liver	Pericardium
A (Vaccination)	*E.coli* serotype	1/20	90%	1,00	0,10	0,20
B (Non Vaccination)	O1K1	14/20	30%	2,80	1,20	1,60
C (Vaccination)	*E.coli* serotype	0/20	100%	0,50	-	0,50
D (Non Vaccination)	O2K1	10/20	50%	1,80	1,60	1,60
E (Vaccination)	*E.coli* serotype	1/20	90%	0,90	0,10	0,30
F (Non Vaccination)	O78K80	11/20	45%	2,00	1,10	1,30

***E. Coli* Challenge Test**

The E. Coli Challenge Test involved two vaccinations at 6 weeks and 16 weeks, each with a 0.5 ml dose administered via intramuscular injection. Organ severity scores were used to assess E. coli infection. A challenge test using 3 different strains of E. coli with a dose of $10^{8.0}$ CFU/0.1 ml was administered via the intra-posterior air thoracic air sac.

Vaccinated chickens showed higher protection rates (90%, 100%, and 90%) compared to non-vaccinated ones (30%, 50%, and 45%), demonstrating Vaksimune Coryza-Coli's effectiveness.

The mean score of three organs (air sacculitis, liver, and pericardium) in the vaccinated group indicated minimal PA lesions, while non-vaccinated chickens had higher scores exceeding 1.5, suggesting the vaccine's ability to inhibit E.coli infection.

vaksindo